Sda Laboratories Tussin

Description

Sdatussin is a pharmaceutical compound with a specific chemical composition. The molecular weight and chemical formula are not provided in the extracted data. The dosage form and appearance of sdatussin are also unspecified. Further details regarding its inactive ingredients and other characteristics are necessary for a comprehensive description.

Uses and Indications

This drug is indicated for the facilitation of mucus clearance in patients with respiratory conditions. It helps to loosen phlegm and thin bronchial secretions, thereby enhancing the productivity of coughs.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

Adults and children over 12 years of age are advised to take 2 teaspoonfuls (10 mL) every 4 hours as needed or as directed by a healthcare professional. It is imperative that no more than 6 doses are taken within a 24-hour period to avoid potential overdose.

For accurate dosing, the provided dosing cup must be used to measure the liquid.

Children under 12 years of age should not use this medication.

Contraindications

There are no specific contraindications listed for this product. However, in the event of an overdose, immediate medical assistance should be sought, or the Poison Control Center should be contacted without delay.

Warnings and Precautions

Healthcare professionals are advised to exercise caution when recommending this medication. It is imperative to consult a physician prior to use in patients presenting with a cough characterized by excessive phlegm (mucus) or in those with a chronic cough associated with conditions such as smoking, asthma, chronic bronchitis, or emphysema.

Should the cough persist beyond 7 days, recur, or be accompanied by additional symptoms such as fever, rash, or a persistent headache, it is crucial to discontinue use and seek medical advice. These symptoms may indicate the presence of a serious underlying condition that requires further evaluation.

In the event of an overdose, immediate medical assistance should be sought, or the Poison Control Center should be contacted without delay to ensure appropriate management.

Healthcare providers should remain vigilant and ensure that patients are informed of these warnings and precautions to promote safe and effective use of the medication.

Side Effects

Patients should be advised to consult a healthcare professional prior to use if they have a cough accompanied by excessive phlegm (mucus) or if they experience a chronic cough, which may be indicative of underlying conditions such as smoking, asthma, chronic bronchitis, or emphysema.

In the event that a cough persists for more than 7 days, recurs, or is accompanied by symptoms such as fever, rash, or a persistent headache, patients are instructed to discontinue use and seek medical advice. These symptoms may signify a serious condition that requires further evaluation.

Drug Interactions

There are no specific drug interactions or laboratory test interactions identified in the available data. Therefore, no recommendations for dosage adjustments or monitoring are necessary at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Sda Laboratories Tussin (guaifenesin). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients under 12 years of age should not be administered this medication. Safety and efficacy have not been established in this age group, and use is contraindicated. Healthcare professionals are advised to consider alternative treatments for pediatric patients in this age range.

Geriatric Use

There is no specific information available regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. It is advisable to monitor these patients closely for any adverse effects or changes in efficacy.

Pregnancy

Pregnant patients and those who are breastfeeding should consult a healthcare professional prior to using this medication. The potential risks and benefits must be carefully weighed, as the effects on fetal outcomes and lactation are not fully established. It is essential for women of childbearing potential to seek medical advice to ensure safe use during pregnancy and lactation.

Lactation

Lactating mothers are advised to consult a health professional prior to using this medication. There is currently no available data on the excretion of this medication in human breast milk or its effects on breastfed infants. Therefore, caution is recommended when administering this medication to lactating mothers.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available data regarding dosage adjustments, special monitoring, or safety considerations. Therefore, healthcare professionals should exercise caution when prescribing this medication to patients with reduced kidney function, as the absence of detailed information necessitates careful clinical judgment and monitoring.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific information regarding overdosage, healthcare professionals are advised to exercise caution and consider the potential risks associated with excessive administration of the medication.

It is essential to monitor patients closely for any signs or symptoms that may arise from an overdose. Symptoms may vary depending on the medication's pharmacological profile and the individual patient's response.

In the event of suspected overdosage, immediate medical intervention is recommended. Healthcare providers should initiate supportive care and symptomatic treatment as necessary. Additionally, contacting a poison control center or a medical toxicologist for guidance on management strategies is advisable.

Documentation of the incident, including the amount ingested and the time of exposure, will aid in the assessment and treatment of the patient. Continuous monitoring of vital signs and laboratory parameters may be warranted to ensure patient safety and to guide further therapeutic interventions.

Overall, vigilance and prompt action are crucial in managing potential overdosage scenarios effectively.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data in these areas limits the understanding of the compound's potential effects in nonclinical settings.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to keep this medication out of reach of children to prevent accidental ingestion. It is crucial to emphasize the importance of safety in the home environment, particularly for households with young children.

In the event of an overdose, healthcare providers should instruct patients to seek medical help immediately or contact a Poison Control Center. Patients should be made aware of the signs of overdose and the urgency of obtaining assistance to ensure their safety and well-being.

Storage and Handling

The product is supplied in a bottle that must be kept tightly closed to maintain its integrity. It should be stored at room temperature, away from direct light to protect its formulation. Once opened, the product should be discarded after use to ensure safety and efficacy.

Additional Clinical Information

The medication is administered orally. For adults and children over 12 years of age, the recommended dosage is 2 teaspoonfuls (10 mL) every 4 hours as needed or as directed by a healthcare professional. It is contraindicated for use in children under 12 years of age.

There is no additional information available regarding laboratory tests, abuse potential, patient counseling, or postmarketing experience.

Drug Information (PDF)

This file contains official product information for Sda Laboratories Tussin, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)